Archive: 03/04/2017
Drug combination shows benefit in RAS-driven cancers
Cancers driven by the RAS oncogene are aggressive and difficult to treat, and thus far precision drugs haven't been able to target the mutant RAS gene successfully.
Apr 3, 2017